1. 30 Jahre Arbeitsgemeinschaft Dermatologische Onkologie (ADO). (22nd October 2021) Authors: Garbe, Claus; Schadendorf, Dirk; Tilgen, Wolfgang; Gutzmer, Ralf; Berking, Carola; Mohr, Peter; Kaufmann, Roland; Breitbart, Eckhard; Weber, Christiane; Volkenandt, Matthias; Hauschild, Axel Journal: Journal der Deutschen Dermatologischen Gesellschaft Issue: Volume 19:Number 11(2021) Page Start: 1682 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 301 Association of response with survival outcomes with atezolizumab in combination with vemurafenib and cobimetinib in the phase 3 IMspire150 study. (9th November 2020) Authors: Ascierto, Paolo; Lewis, Karl; Robert, Caroline; Stroyakovskiy, Daniil; Gogas, Helen; Protsenko, Svetlana; Pereira, Rodrigo; Eigentler, Thomas; Rutkowski, Piotr; Demidov, Lev; Manikhas, Georgy Moiseevich; Li, Haocheng; Zhu, Qian; McKenna, Edward; McNally, Virginia; Gutzmer, Ralf; McArthur, Grant Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A328 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 307 Atezolizumab plus vemurafenib and cobimetinib provides favorable survival outcomes in patients with high tumor mutation burden and proinflammatory gene signature in the phase 3 IMspire150 study. (10th December 2020) Authors: Lewis, Karl; Ascierto, Paolo; Robert, Caroline; Munhoz, Rodrigo; Liszkay, Gabriella; Marino, Luis De La Cruz; Olah, Judit; Queirolo, Paola; Mackiewicz, Jacek; Shah, Kalpit; Forbes, Harper; Hertig, Christian; Yan, Yibing; Gutzmer, Ralf; McArthur, Grant Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A188 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 307 Atezolizumab plus vemurafenib and cobimetinib provides favorable survival outcomes in patients with high tumor mutation burden and proinflammatory gene signature in the phase 3 IMspire150 study. (9th November 2020) Authors: Lewis, Karl; Ascierto, Paolo; Robert, Caroline; Munhoz, Rodrigo; Liszkay, Gabriella; Marino, Luis De La Cruz; Olah, Judit; Queirolo, Paola; Mackiewicz, Jacek; Shah, Kalpit; Forbes, Harper; Hertig, Christian; Yan, Yibing; Gutzmer, Ralf; McArthur, Grant Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A334 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 30 years German Dermatologic Cooperative Oncology Group (DeCOG). (22nd October 2021) Authors: Garbe, Claus; Schadendorf, Dirk; Tilgen, Wolfgang; Gutzmer, Ralf; Berking, Carola; Mohr, Peter; Kaufmann, Roland; Breitbart, Eckhard; Weber, Christiane; Volkenandt, Matthias; Hauschild, Axel Journal: Journal der Deutschen Dermatologischen Gesellschaft Issue: Volume 19:Number 11(2021) Page Start: 1682 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 32. Deutscher Hautkrebskongress der ADO 2022 in Hannover Neue Therapie‐Optionen bei Melanom und anderen Hautkrebsarten. (16th November 2022) Authors: Aldenhoff, Kerstin; Gutzmer, Ralf Journal: Journal der Deutschen Dermatologischen Gesellschaft Issue: Volume 20:Number 11(2022) Page Start: 1560 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. Issue 18 (December 2015) Authors: Johnson, Douglas B.; Menzies, Alexander M.; Zimmer, Lisa; Eroglu, Zeynep; Ye, Fei; Zhao, Shilin; Rizos, Helen; Sucker, Antje; Scolyer, Richard A.; Gutzmer, Ralf; Gogas, Helen; Kefford, Richard F.; Thompson, John F.; Becker, Jürgen C.; Berking, Carola; Egberts, Friederike; Loquai, Carmen; Goldinge... Journal: European journal of cancer Issue: Volume 51:Issue 18(2015:Dec.) Page Start: 2792 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Acute progressive neuropathy–myositis–myasthenia-like syndrome associated with immune-checkpoint inhibitor therapy in patients with metastatic melanoma. Issue 4 (August 2019) Authors: Möhn, Nora; Sühs, Kurt-Wolfram; Gingele, Stefan; Angela, Yenny; Stangel, Martin; Gutzmer, Ralf; Satzger, Imke; Skripuletz, Thomas Journal: Melanoma research Issue: Volume 29:Issue 4(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial. Issue 10358 (1st October 2022) Authors: Livingstone, Elisabeth; Zimmer, Lisa; Hassel, Jessica C; Fluck, Michael; Eigentler, Thomas K; Loquai, Carmen; Haferkamp, Sebastian; Gutzmer, Ralf; Meier, Friedegund; Mohr, Peter; Hauschild, Axel; Schilling, Bastian; Menzer, Christian; Kiecker, Felix; Dippel, Edgar; Roesch, Alexander; Ziemer, Mirj... Journal: Lancet Issue: Volume 400:Issue 10358(2022) Page Start: 1117 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial. Issue 10236 (16th May 2020) Authors: Zimmer, Lisa; Livingstone, Elisabeth; Hassel, Jessica C; Fluck, Michael; Eigentler, Thomas; Loquai, Carmen; Haferkamp, Sebastian; Gutzmer, Ralf; Meier, Friedegund; Mohr, Peter; Hauschild, Axel; Schilling, Bastian; Menzer, Christian; Kieker, Felix; Dippel, Edgar; Rösch, Alexander; Simon, Jan-Chris... Journal: Lancet Issue: Volume 395:Issue 10236(2020) Page Start: 1558 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗